Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
NCT ID: NCT06659445
Last Updated: 2025-12-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
324 participants
INTERVENTIONAL
2025-10-28
2028-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
GA associated with AMD is one of the world's leading causes of visual disability and legal blindness globally. Associated with aging, cigarette smoking, obesity, diets low in certain nutrients, a lifestyle related to cardiac risk, and a growing list of genetic factors, AMD is becoming an increasingly prevalent public health concern, especially as the global population ages. ONL1204 is a first-in-class inhibitor of fragment apoptosis stimulator receptor-mediated cell death that has demonstrated protection of multiple retinal cell types in numerous preclinical models of retinal disease, including models of dry AMD.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
ONL1204 Ophthalmic Solution in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration
NCT04744662
A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT07215234
Intravitreal AAVCAGsCD59 for Advanced Dry Age-related Macular Degeneration (AMD) With Geographic Atrophy (GA)
NCT04358471
A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
NCT03525613
A Phase 2 Study to Assess the Safety and Efficacy of Intravitreal ONL1204 Ophthalmic Solution in Subjects With Mac-off Retinal Detachment
NCT05730218
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ONL1204 Opthalmic solution (1 of 6 Treatment Groups) administered by intravitreal injection
ONL1204 100 µg administered by intravitreal (IVT) injection every 12 weeks
ONL1204 Opthalmic solution
Liquid formulation ONL1204 Ophthalmic Solution administered by intravitreal (IVT) injection
ONL1204 Opthalmic solution (2 of 6 Treatment Groups) administered by intravitreal injection
ONL1204 200 µg administered by intravitreal (IVT) injection every 12 weeks
ONL1204 Opthalmic solution
Liquid formulation ONL1204 Ophthalmic Solution administered by intravitreal (IVT) injection
ONL1204 Opthalmic solution (3 of 6 Treatment Groups) administered by intravitreal injection
ONL1204 200 µg administered by intravitreal (IVT) injection every 24 weeks
ONL1204 Opthalmic solution
Liquid formulation ONL1204 Ophthalmic Solution administered by intravitreal (IVT) injection
Sham Comparator (4 of 6 Treatment Groups)
Sham injection every 12 weeks
Sham
Sham injection
Sham Comparator (5 of 6 Treatment Groups)
Sham injection every 24 weeks
Sham
Sham injection
Avacincaptad pegol intravitreal solution (6 of 6 Treatment Groups - US ONLY)
Avacincaptad pegol administered by intravitreal (IVT) injection - (2 mg (0.1 mL of 20 mg/mL solution) once monthly
Avacincaptad Pegol intravitreal solution
Liquid formulation Avacincaptad Pegol administered by intravitreal (IVT) injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ONL1204 Opthalmic solution
Liquid formulation ONL1204 Ophthalmic Solution administered by intravitreal (IVT) injection
Avacincaptad Pegol intravitreal solution
Liquid formulation Avacincaptad Pegol administered by intravitreal (IVT) injection
Sham
Sham injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Able and willing to give informed consent and attend study visits.
3. Women or intersex individuals must be willing to use 2 forms of effective contraception during the study and for at least 90 days following the last dose of study drug, be postmenopausal for at least 12 months prior to study entry, or surgically sterile. If of childbearing potential, a negative urine pregnancy test is required at Screening and prior to the administration of study drug at each visit.
4. Men or intersex individuals with partners of childbearing potential must be willing to use permissible methods of contraception and refrain from sperm donation during the study and for at least 90 days following the last dose of study drug.
5. If currently using Age-related Eye Disease Study 2 (AREDS, AREDS2, or similar nutraceutical therapy at Screening, patient must be willing to continue use for the duration of the study. If not currently using AREDS2 or similar, patient must be willing to continue not to use therapy for the duration of the study. Patient must agree to choose either approach.
6. BCVA of 24 letters or more using ETDRS charts in the study eye at Screening.
7. Intraocular pressure (IOP) of 22 mmHg or lower in the study eye at Screening.
The GA lesion must meet all the following criteria:
8. Non-foveal GA associated with AMD without eMNV in the study eye per Investigator's evaluation and as confirmed by the central RC.
9. GA ≥0.85 disc area (DA) (2.125 mm2) and ≤8.05 DA (20.125 mm2) in the study eye as confirmed by the central RC.
10. If GA in the study eye is multifocal, at least 1 focal lesion must be ≥0.425 DA (1.063 mm2) as confirmed by the central RC.
11. Non-foveal GA (GA lesion up to the fovea, but not subfoveal) with the lesion's closest border 1725 microns or less from the foveal center in the study eye, as confirmed by the central RC.
12. The entire GA lesion in the study eye must be completely visualized on the macula-centered FAF image, must be able to be imaged in its entirety, and must not be contiguous with any areas of peripapillary atrophy per the Investigator's evaluation and as confirmed by the central RC.
13. A pattern of hyper-autofluorescence in the junctional zone of GA in the study eye must be present as confirmed by the central RC.
Fellow Eye Inclusion Criterion:
14. BCVA of 19 letters or more using ETDRS charts in the fellow eye at Screening.
Exclusion Criteria
2. Previous ophthalmic disease gene therapy or planned participation in any gene therapy clinical study during the study period.
3. Current or planned use of systemic complement inhibitors during the study period.
4. Any ocular or systemic condition that, in the opinion of the Investigator, makes the patient unsuitable for treatment with an investigational drug or that would compromise the safety or efficacy assessments of the study.
5. Treatment with any ocular or systemic medication that is known to be toxic to the lens, retina, or optic nerve (including, but not limited to, aminoglycosides, vancomycin, hydroxychloroquine, interferon, tacrolimus, cisplatin, bis-chloroethyl nitrosourea, carmustine, ethambutol, and tamoxifen) within 90 days prior to Screening or anticipated during the study period.
6. Any previous treatment of pentosan polysulfate (Elmiron®) is exclusionary.
7. Known allergy to fluorescein, povidone iodine, or any ingredients of the study drug or avacincaptad pegol intravitreal solution.
8. Individuals who are currently pregnant, planning to become pregnant, or are nursing at Screening or during the study period.
9. Active ocular or periocular infection in the study eye.
10. Any contraindication to an IVT injection in the study eye.
11. Any media opacity in the study eye that limits visual acuity, clinical visualization of the retina, or retinal imaging as determined by the Investigator.
12. Previous IVT pharmaceutical treatment in the study eye with any agent except Food and Drug Administration (FDA)-approved complement inhibitors and treatment with FDA-approved complement inhibitors within 12 weeks prior to Screening.
13. Any history of incisional retinal surgery in the study eye including but not limited to scleral buckle or vitrectomy. (Retinal laser for a tear or hole 3 months or more prior to Screening is not exclusionary).
14. History of incisional glaucoma surgery including trabeculectomy, tube shunt, or minimally invasive glaucoma surgery in the study eye. (Glaucoma laser procedures performed at least 6 months prior to Screening are not exclusionary).
15. Yttrium aluminum garnet capsulotomy in the study eye within 1 month prior to Screening.
16. Cataract surgery in the study eye planned or expected during the study period.
17. Aphakia with absence of the posterior capsule in the study eye. (Pseudophakia with an open posterior capsule is not exclusionary).
18. Any current evidence or history in the study eye of exudative ("wet") AMD, including any RPE rips or evidence of actively leaking neovascularization anywhere in the retina based on the FA or SD-OCT as assessed per the Investigator's evaluation and confirmed by the central RC.
19. Any clinically significant retinal disease other than AMD except benign degenerative conditions (eg, Cobblestone degeneration) in the study eye.
21. Previous therapeutic radiation (including transpupillary thermotherapy, photodynamic therapy, or external-beam) in the region of the study eye.
Fellow Eye Exclusion Criterion:
22. Planned or expected IVT injection in the fellow eye for treatment of GA with agents other than FDA-approved complement inhibitors (pegcetacoplan or avacincaptad pegol IVT solution \[Izervay™\]) during the study period.
23. Active intraocular inflammation in either eye or a history of uveitis or endophthalmitis in either eye.
24. GA in either eye due to causes other than AMD.
25. Any ophthalmic condition in either eye that is likely to require surgery during the study period.
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ONL Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Associated Retina Consultants
Gilbert, Arizona, United States
Associated Retina Consultants
Phoenix, Arizona, United States
Doheny Image Reading Center
Pasadena, California, United States
Bay Area Retina Associates
Walnut Creek, California, United States
Retina Consultants of Southern Colorado
Colorado Springs, Colorado, United States
Retina Group of New England
Waterford, Connecticut, United States
Florida Retina Institute
Orlando, Florida, United States
Retina Associates, Ltd.
Elmhurst, Illinois, United States
Retina Partners Midwest, P.C.
Carmel, Indiana, United States
Retina Research Institute at New England Retina Consultants
Springfield, Massachusetts, United States
Associated Retinal Consultants, P.C.
Royal Oak, Michigan, United States
The Retina Institute
St Louis, Missouri, United States
Sierra Eye Associates
Reno, Nevada, United States
Retina Associates of Western NY
Rochester, New York, United States
Long Island Vitreoretinal Consultants
Westbury, New York, United States
North Carolina Retina Associates, S.C.
Wake Forest, North Carolina, United States
Erie Retina Research, LLC (Clinic)
Erie, Pennsylvania, United States
Charleston Neuroscience Institute
Mt. Pleasant, South Carolina, United States
Palmetto Retina Center
West Columbia, South Carolina, United States
Retina Consultants of Texas
Beaumont, Texas, United States
Retina Consultants of Texas
Bellaire, Texas, United States
Retina Consultants of Texas
Katy, Texas, United States
Retina Associates of South Texas, PA
San Antonio, Texas, United States
Retina Consultants of Texas
San Antonio, Texas, United States
Retina Consultants of Texas
The Woodlands, Texas, United States
Pacific Northwest Retina
Bellevue, Washington, United States
Pacific Northwest Retina, PLLC
Silverdale, Washington, United States
Clinique d'ophtalmologie des Laurentides
Boisbriand, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ONL1204-GA-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.